UPB Upstream Bio, Inc.

NASDAQ
$3.38

Upstream Bio, Inc. (UPB) is expected to report earnings on November 4, 2026, before the market open. The consensus earnings estimate is a loss of $0.66 per share.

Upstream Bio Missed Consensus Estimates
Tuesday, November 10, 2026 · 7:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Nov 4
Wednesday · 7:00 AM ET
Earnings Whisper
-
vs ($0.66)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $4.54

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Upstream Bio, Inc.

Upstream Bio Inc. is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in development which targets the receptor for thymic stromal lymphopoietin, a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. Upstream Bio Inc. is based in WALTHAM, Mass.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.